| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/14/2004 | US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues |
| 10/14/2004 | US20040202640 Method for topical treatment of scars with rotein Kinase C inhibitors |
| 10/14/2004 | US20040202639 Facially amphiphilic polymers as anti-infective agents |
| 10/14/2004 | US20040202624 Galenical formulation |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | US20040202616 comprises magnesium stearate for improved storage stability; inhalers |
| 10/14/2004 | US20040202609 administering a cytotoxic compound of porphyrin complexed with a radioactive metal to a mammal; treating arteriosclerotic lesions; radioactive metal is cytotoxic to cells in and surrounding the plaque |
| 10/14/2004 | DE20315266U1 Powdered laxative composition based on plantago seeds and sennoside compounds, also containing polygalactomannan to facilitate suspension in water and improve activity |
| 10/14/2004 | DE202004012450U1 Delivery unit for administering a medicament into the vaginal cavity of a patient comprises an elongate body with delivery and grip ends, a medicament container, and a piston system |
| 10/14/2004 | DE10315572A1 Substituierte Pyrazole Substituted pyrazoles |
| 10/14/2004 | DE10315570A1 New 1-aryl-1,2,3-triazole derivatives useful for treating e.g. schizophrenia, depression, dementia, Parkinson's disease or Alzheimer's disease, are glycine transporter inhibitors |
| 10/14/2004 | DE10314976A1 Verbesserte Penetration von Wirkstoffen in Zellen und Organe Improved penetration of active substances into cells and organs |
| 10/14/2004 | DE10314617A1 Verwendung des Hydrochlorids der Wirkstoffbase Use of the hydrochloride of the active substance base 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne in combination with sumatriptan for migraine |
| 10/14/2004 | DE10313446A1 Phenazon-haltiges Migränemedikament Phenazone-containing migraine medication |
| 10/14/2004 | DE10295684T9 Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 Method for the specific inhibition of histone deacetylase 4 |
| 10/14/2004 | CA2527130A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 10/14/2004 | CA2527126A1 Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| 10/14/2004 | CA2523126A1 Thiazoles useful as inhibitors of protein kinases |
| 10/14/2004 | CA2523125A1 Thiazoles useful as inhibitors of protein kinases |
| 10/14/2004 | CA2522441A1 Hif-1 inhibitors |
| 10/14/2004 | CA2521371A1 Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| 10/14/2004 | CA2521274A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 10/14/2004 | CA2521261A1 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases |
| 10/14/2004 | CA2521260A1 Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials |
| 10/14/2004 | CA2521253A1 Pharmaceutical compositions having reduced bitter taste |
| 10/14/2004 | CA2521250A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 10/14/2004 | CA2521221A1 Method for the treatment of prostate cancer |
| 10/14/2004 | CA2521220A1 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains |
| 10/14/2004 | CA2521191A1 Pyrrolo (1,2-b) pyridazine compounds and their use as cfr-1 receptor antagonists |
| 10/14/2004 | CA2521172A1 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 10/14/2004 | CA2521073A1 Chemical compounds for the treatment of chemokine mediated disease state |
| 10/14/2004 | CA2521056A1 Hydrazone derivative |
| 10/14/2004 | CA2521055A1 Methyl-.beta.-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
| 10/14/2004 | CA2521052A1 Nitric oxide in treatment of inflammation |
| 10/14/2004 | CA2521050A1 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| 10/14/2004 | CA2521046A1 Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease |
| 10/14/2004 | CA2521014A1 Combination drug therapy for treating hypertension |
| 10/14/2004 | CA2520997A1 Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| 10/14/2004 | CA2520960A1 Use of atii antagonist for the treatment or prevention of metabolic syndrome |
| 10/14/2004 | CA2520957A1 Method for treating vascular hyperpermeable disease |
| 10/14/2004 | CA2520932A1 Dosage forms comprising ag013736 |
| 10/14/2004 | CA2520930A1 Use of the hydrochloride of the active ingredient base 1-[n<sp>2</sp>-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines |
| 10/14/2004 | CA2520900A1 Pyrrolo[1,2-b]pyridazine compounds and their use as crf1 receptor antagonists |
| 10/14/2004 | CA2520899A1 Pyrrolo[1,2-b]pyridazine compounds and their uses |
| 10/14/2004 | CA2520896A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase |
| 10/14/2004 | CA2520894A1 Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses |
| 10/14/2004 | CA2520828A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 10/14/2004 | CA2520724A1 Benzopyran compounds useful for treating inflammatory conditions |
| 10/14/2004 | CA2520686A1 Therapeutic and/or preventive agent for pulmonary disease |
| 10/14/2004 | CA2520682A1 Crystalline n-formyl hydroxylamine compounds |
| 10/14/2004 | CA2520680A1 Antitussives |
| 10/14/2004 | CA2520658A1 A method and kit for detecting the early onset of renal tubular cell injury |
| 10/14/2004 | CA2520627A1 Composition for preventing or treating allergic disease using black rice extract and its therapeutic use |
| 10/14/2004 | CA2520581A1 Cyclic benzimidazoles |
| 10/14/2004 | CA2520577A1 Pharmaceutical composition |
| 10/14/2004 | CA2520568A1 Indolone-acetamide derivatives, processes for preparing them and their uses |
| 10/14/2004 | CA2520525A1 Ophthalmic drug delivery system using polymer micelle |
| 10/14/2004 | CA2520521A1 Preserved ophthalmic compositions |
| 10/14/2004 | CA2520493A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 10/14/2004 | CA2520465A1 Bi-cyclic pyrimidine inhibitors of tgf.beta. |
| 10/14/2004 | CA2520460A1 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| 10/14/2004 | CA2520423A1 Treatment of demyelinating conditions |
| 10/14/2004 | CA2520406A1 Cxcr4 antagonists and methods of their use |
| 10/14/2004 | CA2520377A1 Migrastatin analog compositions and uses thereof |
| 10/14/2004 | CA2520375A1 Anti-obesity agent |
| 10/14/2004 | CA2520321A1 Oral extended release compressed tablets of multiparticulates |
| 10/14/2004 | CA2520291A1 Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use |
| 10/14/2004 | CA2520192A1 Degradation products of azithromycin, and methods for their identification |
| 10/14/2004 | CA2520181A1 Selected rna motifs to include cell death and/or apoptosis |
| 10/14/2004 | CA2520125A1 Muscarinic m1 receptor agonists for pain management |
| 10/14/2004 | CA2520124A1 Use of benzazole compounds for immunopotentiation |
| 10/14/2004 | CA2519998A1 Topical l-carnitine compositions |
| 10/14/2004 | CA2519958A1 Pharmaceutical composition comprising a macrolide immunomodulator |
| 10/14/2004 | CA2519954A1 Benzamide modulators of metabotropic glutamate receptors |
| 10/14/2004 | CA2519899A1 Ophthalmic compositions for treating ocular hypertension |
| 10/14/2004 | CA2519869A1 Taste-masking vehicle for coated oxazolidinone particles |
| 10/14/2004 | CA2519515A1 Benodiazepine spirohydantoin cgrp receptor antagonists |
| 10/14/2004 | CA2519301A1 Oxime derivatives and their use as pharmaceutically active agents |
| 10/14/2004 | CA2519291A1 Chromene derivatives as anti-inflammatory agents |
| 10/14/2004 | CA2519106A1 Formulations for tyrosine kinase inhibitors |
| 10/14/2004 | CA2519096A1 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease |
| 10/14/2004 | CA2518913A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| 10/14/2004 | CA2518872A1 Devices, methods, and compositions to prevent restenosis |
| 10/14/2004 | CA2518533A1 Oral suspension of tegaserod |
| 10/14/2004 | CA2518465A1 Dipeptidyl peptidase inhibitors |
| 10/14/2004 | CA2518270A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof |
| 10/14/2004 | CA2518245A1 Synergistic combinations of macrolide t-cell modulator or inmunosuppressant and a retinoid |
| 10/14/2004 | CA2517487A1 Inhibitors of phosphodiesterases in infertility |
| 10/14/2004 | CA2517102A1 Kit for pharmaceutical use |
| 10/14/2004 | CA2516429A1 Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
| 10/14/2004 | CA2464175A1 Methods and compositions for modulating proteins modified in preconditioning against ischemia/hypoxia |
| 10/13/2004 | EP1466968A2 Method and apparatus for encapsulation of biologically-active substances |
| 10/13/2004 | EP1466917A1 Method for making peptide boronic acids and acids obtainable thereby |
| 10/13/2004 | EP1466916A1 Peptide boronic acids useful in making salts thereof |
| 10/13/2004 | EP1466915A1 Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier |
| 10/13/2004 | EP1466913A1 Benzoylecgonine, ecgonine and ecgonidine derivatives |
| 10/13/2004 | EP1466912A1 2-acylaminothiazole derivative or salt thereof |
| 10/13/2004 | EP1466911A2 Preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 10/13/2004 | EP1466909A1 Halogenobenzyl aminopropionic acid derivatives |
| 10/13/2004 | EP1466906A1 Heterocyclic urea and related compounds useful as anti-inflammatory agents |